Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3126)	6/1/1999 12:39:00 PM
From: LLCF	Respond to of 10280

<Kimmel's explanation: With a developmental stage biotech company, 7.4% might as well be nothing. > So they take no responsibility for printing Kimmel's stuff, they just blame him. Do they say anywhere who he's with... or just "analyst"? DAK

To: Biomaven who wrote (3126)	6/1/1999 12:50:00 PM
From: Vector1	Read Replies (1) \| Respond to of 10280

<<With a developmental stage biotech company, 7.4% might as well be nothing.>> That may be one of the stupidest quotes I have heard in a long time. 7.4% of 2 billion is almost $150 million. V1

To: Biomaven who wrote (3126)	6/1/1999 2:43:00 PM
From: Harold Engstrom	Respond to of 10280

Concur with V1 about quality of remark. Furthermore, IS Sepracor a developmental stage biotech company? I don't think a company that has brought something through clinicals to approval is a developmental stage biotech company anymore. Certainly Sepracor is still developing, but it is an operating company now and not early stage any longer. I took the street.com up on their free trial offer and its pretty underwhelming stuff.

To: Biomaven who wrote (3126)	6/3/1999 4:21:00 PM
From: RCMac	Read Replies (2) \| Respond to of 10280

"Chalk One Up for Sepracor's Shorts" - more shoddy journalism, this time from the 6/21/99 Fortune, and featuring BS's David Maris: pathfinder.com "'Up until J&J, the majority of people believed that most deals were pretty solid,' says Bear Stearns' David Maris, the only analyst until recently with anything less than a "buy" rating on Sepracor (and now the only one with an outright "sell"). One day after the J&J news, analysts shaved earnings estimates for 2000 by 24 cents, according to First Call. Three Sepracor board members have sold their holdings, and hedge fund manager Mike DiCarlo has completely wiped out his position for now." Careless, to put it gently, to say the "board members have sold their holdings." In fact, three outside directors have each sold a portion of their holdings, on the order of 30-35% each, and retained more than 20,000 shares each. --RCM